B cells are central players in both humoral and cellular immunity, traditionally recognized for their role in antibody production. However, recent research highlights their direct involvement at sites of inflammation, where they establish tissue-resident memory populations and contribute to immune responses in infection, inflammatory diseases, and cancer. The spatial organization of B cells within tissues significantly influences their function, disease progression, and therapeutic outcomes.
Last week, researchers from Oregon Health & Science University published a paper describing how B cells do more than simply produce antibodies. They also play a role in peripheral tissues in homeostasis and disease, and the researchers identified cellular and molecular signals that are involved in regulating their activity. Multi-omic analyses and in vivo fate mapping reveal that B cells infiltrate non-lymphoid tissues and tumors, undergoing in situ differentiation into memory B cells and plasma cells that shape local immune responses through cytokine and antibody production. These cells also act as tissue sentinels, prepared for future immune challenges. Their function is influenced by interactions within lymph node-like structures, such as tertiary lymphoid structures (TLSs), which regulate their role in disease. However, key aspects of tissue B cell biology remain unclear, including reliable markers for identifying BRM cells and the molecular signals that control their maintenance. Understanding TLS maturation and BRM cell differentiation could advance immunotherapy, enhancing protection against infections and strengthening B cell-driven anticancer immunity. Recognizing the localized nature of B cell function adds critical depth to our understanding of their immunological impact.
DOI: 10.1038/s41577-025-01137-6
Meanwhile, researchers from the University of Southern California found how B cells can be reprogrammed through genome editing to produce custom heavy-chain-only antibodies beyond what is achievable through immunization. This approach allows modifications to both the antigen-binding and Fc domains, expanding the potential for engineered antibody designs. Using HIV envelope protein as a model, they demonstrated that edited B cells maintain regulated B cell receptor expression and antigen responsiveness in a tonsil organoid model. However, dual expression of endogenous and engineered antibodies raises safety concerns, including potential competition and self-reactivity. While naturally occurring dual BCR B cells exist, their role in autoimmunity remains unclear. This study presents a simplified genome-editing strategy for engineering B cells with flexible antibody designs, paving the way for novel therapeutic applications while necessitating further investigation into safety and efficacy.
DOI: 10.1038/s41551-024-01240-4
Another recent study led by researchers from Northwestern University explored the potential of B cell–based therapy that produces antibodies to inhibit glioblastoma growth. BVax, a B cell-based vaccine, effectively migrates to GBM tumors, differentiates into antibody-secreting plasmablasts, and produces antibodies that target extracellular matrix (ECM) components critical for tumor invasion and motility. These antibodies inhibit GBM cell migration and invasion, demonstrating therapeutic potential. BVax-derived antibodies also recognize both extracellular and cytoplasmic antigens, though the mechanism behind this remains unclear. Beyond antibody responses, BVax may also enhance CD8+ T cell activation, contributing to its antitumor effects. Despite variability in antigenic reactivity among patients, BVax consistently targets key regulators like fibrinogen and collagens. Future research should focus on optimizing BVax's efficacy in GBM’s immune-suppressive environment and identifying additional tumor antigens for therapeutic development.
